Opening book details…
Can I read Liver Cancer: Hepatocellular and Fibrolamellar Carcinoma on EtoBox?
Liver Cancer: Hepatocellular and Fibrolamellar Carcinoma by Aaron Coleman; Elainea N. Smith; Samuel J. Galgano; Kristin K. Porter is a book available to read on EtoBox.
What is Liver Cancer: Hepatocellular and Fibrolamellar Carcinoma about?
Hepatocellular carcinoma (HCC) is a common cancer worldwide. HCC typically develops in patients with background liver disease. Fibrolamellar hepatocellular carcinoma (FLHCC) is an uncommon subtype of HCC that disproportionally affects younger patients without chronic liver disease. The proper management of HCC requires a multidisciplinary team with input from the radiologist, oncologist, surgeon, interventional radiologist, and pathologist. This team approach helps in patient selection for surgical and nonsurgical treatment. For the nonsurgical approach, both systemic and directed therapy should be considered, and the best option should be tailored to the individual patient. Advances in imaging techniques are leading to improved selection of patients for appropriate therapies. Newer, nonsurgical therapies are also in development and early implementation. Improvements in these and other therapeutic approaches may permit longer survival or allow patients with downgraded tumors to receive surgical options that would not have been otherwise feasible. In patients with FLHCC, the diagnosis may be suggested by imaging, but it is confirmed by histology. The prognosis for FLHCC is better th
- Author
- Aaron Coleman; Elainea N. Smith; Samuel J. Galgano; Kristin K. Porter
- Publisher
- Elsevier
- Published
- 2023
- Language
- EN
More by Aaron Coleman; Elainea N. Smith; Samuel J. Galgano; Kristin K. Porter
Browse all works by Aaron Coleman; Elainea N. Smith; Samuel J. Galgano; Kristin K. Porter
Similar books
- Progress in Hepatocellular Carcinoma Treatment — Kiwamu Okita; Yamaguchi Symposium on Liver Diseases (2012)
- Hepatic TM6SF2 Activates Antitumour Immunity to Suppress Metabolic Dysfunction-associated Steatotic Liver Disease-related Hepatocellular Carcinoma and Boosts Immunotherapy — Yating Zhang (2025)
- Updates on the Staging and Treatment of Hepatocellular Carcinoma — Hariharasudan Mani; Saeed Ali; Sarfraz Ahmad (2022)
- Hepatocellular Carcinoma (HCC): Epidemiology, Etiology and Molecular Classification — Saranya Chidambaranathan-Reghupaty; Paul B. Fisher; Devanand Sarkar (2021)
- Nanotherapeutics for the Treatment of Hepatocellular Carcinoma — Mukherjee Biswajit (2022)
- An Overview on Aflatoxin B1 Induced Initiation and Progression of Hepatocellular Carcinoma — Chintapanti Swetha; Bala Prabhakar Girish (2022)